Vineet Laboratories Ltd

On 02-Jan, Vineet Laboratories Ltd witnessed a notable decline in its share price, closing at ₹34.28, down ₹1.49 or 4.17% from the previous session. This drop reflects a continuation of a downward trend influenced by deteriorating financial performance and waning promoter confidence.

As of 18-Nov, Vineet Laboratories Ltd's stock price is Rs 41.23, down 2.53%, and has declined 10.27% over the last four days. The company faces significant challenges, including negative returns over the past year and weak fundamentals, contributing to a lack of investor confidence.

As of 14-Nov, Vineet Laboratories Ltd's stock price is declining at 43.43, down 0.89%, with a total return of -5.48% over the last two days. The stock has significantly underperformed year-to-date and over the past year compared to the Sensex, indicating a challenging environment.

Vineet Laborator has experienced a significant decline in financial performance, with net sales dropping from 243.48 Cr in March 2021 to 75.00 Cr in March 2025, resulting in a loss of 20.19 Cr after tax. Despite a slight recovery in cash flow from operating activities, the overall financial position remains weak.

Vineet Laboratories' latest results show a mixed picture: while the company achieved a net profit of ₹0.40 crores, a turnaround from a loss, it faces declining revenues and significant structural challenges, raising concerns about its financial health and future prospects.

Vineet Laborator has experienced significant declines in revenue and profitability, with net sales dropping from 243.48 Cr in Mar'21 to 75.00 Cr in Mar'25, resulting in negative earnings and cash flow in the latest fiscal year. Total assets and liabilities have also decreased, reflecting a challenging financial period for the company.

As of 28-Oct, Vineet Laboratories Ltd is currently priced at 45.65, reflecting a 1.69% increase and strong recent performance with an 8.43% gain over two days. Despite short-term gains, the stock has a year-to-date decline of 26.78%, contrasting with the Sensex's increase of 8.30%.

Vineet Laborator has experienced significant declines in net sales and profitability, with net sales dropping from INR 243.48 crore in March 2021 to INR 75.00 crore in March 2025, resulting in an operating profit of -INR 14.29 crore and a profit after tax of -INR 20.19 crore. Despite these challenges, cash flow from operating activities turned positive at INR 11.00 crore in March 2025.

As of 27-Oct, Vineet Laboratories Ltd is seeing a price increase to Rs 44.54, up 5.8%, after outperforming its sector today. Despite recent gains, the stock has a year-to-date decline of 28.56% and a significant drop in delivery volume, indicating mixed investor sentiment.

Vineet Laborator has experienced significant financial decline, with net sales dropping from INR 243.48 crore in March 2021 to INR 75.00 crore in March 2025, resulting in negative operating profit and profit after tax of INR -20.19 crore. Despite a slight decrease in total liabilities and an improvement in cash flow from operating activities, the company has struggled with profitability and sales performance.

As of 20-Oct, Vineet Laboratories Ltd is seeing a price increase to Rs 41.69, up 2.91%, with a recent two-day gain of 6.52%. Despite this short-term rise, the stock has a year-to-date decline of -33.14% and has underperformed compared to the benchmark Sensex over the longer term.

As of 08-Oct, Vineet Laboratories Ltd is priced at 39.90, showing a slight increase but has underperformed recently with a 5.61% drop over the past week and negative results for five consecutive quarters. Weak financial performance and declining investor interest suggest that the recent upward movement may not be sustainable.

As of 01-Oct, Vineet Laboratories Ltd is currently priced at Rs 42.12, reflecting a recent short-term gain of 20.03%. However, the company faces significant long-term challenges, including declining operating profits and promoter confidence, despite outperforming the Sensex in the short term.